Parsippany, NJ, March 24, 2026 (Yahoo Finance) -- Embecta has agreed to acquire Owen Mumford to strengthen its drug-delivery business. The transaction, valued at approximately $300 million, will add a range of injection and medical device products to Embecta’s portfolio. The deal is expected to enhance the company’s capabilities in supporting patients with chronic conditions. Read full article here .

Brisbane, CA, April 7, 2026 (ImpediMed) — ImpediMed has named Erik Anderson as its new chief executive officer. The leadership change is intended to guide the company’s strategic direction and support expansion of its medical technology portfolio. The appointment comes as ImpediMed focuses on advancing its commercial operations and growth initiatives. Read full article here .

San Diego, CA, April 7, 2026 (Yahoo Finance) -- Neurocrine Biosciences has outlined a transaction valued at approximately $2.9 billion aimed at expanding its therapeutic portfolio. The deal is designed to enhance the company’s pipeline with additional clinical-stage assets. The move supports Neurocrine’s strategy to drive long-term growth through targeted business development initiatives. Read full article here .

Marlborough, MA and New York, NY, April 7, 2026 (Business Wire) -- Hologic announced the close of its go-private acquisition by Blackstone and TPG at up to $79/share and simultaneously named José (Joe) Almeida as CEO, effective immediately. Almeida was previously Chairman/President/CEO of Baxter International (2016–2025) and before that CEO of Covidien through its Medtronic acquisition. He succeeds Steve MacMillan, who retired after 12+ years. Read full article here .

Foster City, CA and Munich, Germany, April 7, 2026 (Business Wire) -- Gilead Sciences has announced plans to acquire Tubulis to enhance its cancer treatment portfolio. The deal includes $3.15 billion in upfront cash, along with potential milestone payments that could bring the total value significantly higher. The acquisition adds advanced antibody-drug conjugate (ADC) candidates and platform technologies aimed at strengthening Gilead’s next-generation oncology pipeline. Re

Chicago, IL, March 18, 2026 (Business Wire) -- GE HealthCare has finalized its $2.3 billion acquisition of Intelerad, a provider of medical imaging software solutions. The addition strengthens its presence in cloud-based imaging and extends capabilities into ambulatory and teleradiology markets. The company expects the business to generate substantial recurring revenue in its first full year under ownership. Read full article here .

Boston, MA, March 23, 2026 (Globe Newswire) -- Damora Therapeutics has appointed Jennifer Jarrett as president and chief executive officer, effective at the end of March. She brings extensive experience from prior leadership roles in biotech and investment banking. The company aims to leverage her expertise to advance its biologics pipeline for blood disorders. Read full article here .

Foster City, CA, March 23, 2026 (Business Wire) -- Gilead Sciences has entered an agreement to acquire Ouro Medicines in a deal valued at up to $1.7 billion. The acquisition is designed to enhance its development of T-cell engager therapies targeting autoimmune diseases. Integrating Ouro’s platform is expected to accelerate progress on novel immunology treatments. Read full article here .

Cardiff-by-the-Sea, CA, March 16, 2026 (PR Newswire) -- Field Medical has named Mark A. Turco, MD, as its new chief executive officer. He brings decades of leadership experience across cardiovascular and medical device companies. The appointment is intended to advance the company’s pulsed field ablation technology for treating complex cardiac arrhythmias. Read full article here .

Rahway, NJ and Foster City, CA, March 25, 2026 (Business Wire) -- Merck has agreed to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion. The deal adds TERN-701, an investigational oral therapy for chronic myeloid leukemia, to Merck’s oncology pipeline. The transaction is expected to close in the second quarter of 2026, pending customary conditions. Read full article here .

Santa Clara, CA & San Francisco, CA, March 9, 2026 (Business Wire) -- Agilent Technologies announced it has agreed to acquire Biocare Medical for $950 million in cash, expanding its portfolio in clinical and research pathology solutions. Biocare develops antibodies, reagents, and instruments used in technologies such as immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH), and generated over $90 million in revenue in 2025 wh

Dedham, MA, March 1, 2026 (Business Wire) -- Qlaris Bio has appointed Fred Guerard, Pharm.D., as president and chief executive officer, effective March 1, 2026, and he will also join the company’s board of directors. Guerard brings more than 20 years of leadership experience in ophthalmology and biotechnology, with a focus on advancing innovative therapies through late-stage development and commercialization. He succeeds Thurein Htoo, who helped establish the company and ad

Suresnes, France & Brisbane, CA, March 6, 2026 (Globe Newswire) -- Servier has agreed to acquire Day One Biopharmaceuticals for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The acquisition strengthens Servier’s rare oncology portfolio, particularly in pediatric low-grade glioma, and adds several oncology programs spanning early development through Phase 3. The transaction, expected to close in the second quarter of 2026, combine

Copenhagen, March 4, 2026 (Coloplast) -- Coloplast has appointed Gavin Wood as President and Chief Executive Officer, effective May 1, 2026, succeeding interim CEO Lars Rasmussen. Wood joins after more than 20 years at Johnson & Johnson, most recently serving as Company Group Chairman of Johnson & Johnson MedTech EMEA, overseeing a multi-billion-dollar business spanning surgery, orthopedics, and cardiovascular solutions. He will relocate to Denmark as he takes over leadersh

Dublin, Ireland, March 10, 2026 (Reuters) -- Medtronic announced plans to acquire Scientia Vascular for approximately $550 million, expanding its portfolio of devices used to treat stroke. The Salt Lake City–based company develops specialized guidewires and catheters designed to navigate delicate blood vessels in the brain, technologies that will integrate with Medtronic’s existing neurovascular product line. The transaction, expected to close in the first half of fiscal 20

London, February 25, 2026 (Proactive) -- GSK has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, adding a clinical-stage pulmonary hypertension therapy to its pipeline. The company believes the drug could offer a safer alternative to existing treatments, which are often limited by bleeding complications. The global pulmonary hypertension market is projected to reach $18 billion by 2032. The centerpiece of the deal is HS235, an activin signaling inhibit

Boca Raton, FL, February 18, 2026 (Globe Newswire) -- LIXTE Biotechnology Holdings, Inc., a clinical-stage oncology company developing small-molecule cancer therapies and radiotherapy technologies, announced the appointment of Sidney Braun as Chief Executive Officer of its European subsidiary, Liora Technologies Europe Ltd.. Braun brings more than two decades of healthcare operational and strategic experience and previously played a key role in establishing Liora and facili

Waltham, MA, February 18, 2026 (Business Wire) -- Korsana Biosciences announced it has emerged from stealth mode with $175 million in total funding to advance novel therapies for neurodegenerative diseases, initially focusing on Alzheimer’s disease. The financing includes a $25 million seed round in 2024 led by Fairmount and Venrock Healthcare Capital Partners, followed by a $150 million Series A in September 2025 co-led by Wellington Management and TCGX, with participation

Paris, February 12, 2026 (Sanofi) -- Sanofi has named Belen Garijo as its next Chief Executive Officer, following the Board’s decision not to renew Paul Hudson’s mandate. Hudson will step down on February 17, 2026, after six years leading the company’s strategic transformation. Garijo will officially assume the CEO role after the Annual General Meeting on April 29, 2026, subject to shareholder approval of her nomination to the Board. During the interim period, Olivier Charm

Washington, February 17, 2026 (PRNewswire) -- Danaher Corporation announced it has signed a definitive agreement to acquire Masimo Corporation, a leader in pulse oximetry and advanced patient monitoring technologies, in an all-cash deal valued at approximately $9.9 billion, including assumed debt. Under the agreement, Danaher will pay $180 per share in cash, representing a transaction multiple of roughly 18x estimated 2027 EBITDA, or 15x including expected synergies. Masimo